nesiritide + standard care + dobutamine or milrinone

This is a combination therapy approach for treating acutely decompensated heart failure. It includes nesiritide (a recombinant human B-type natriuretic peptide) along with standard care plus either dobutamine or milrinone (both inotropic agents). Nesiritide works by binding to receptors in the vasculature, kidney, adrenal gland, and brain, leading to increased intracellular concentrations of cGMP and smooth muscle cell relaxation. This produces vasodilation, natriuresis, and diuresis, resulting in decreased cardiac filling pressures and improved symptoms. Dobutamine improves myocardial contractility via activation of β1-adrenergic receptors in cardiomyocytes, while milrinone is a phosphodiesterase-3 inhibitor that improves contractility without affecting β1-receptors. This combination approach would typically be used in patients with severe heart failure symptoms and hemodynamic compromise requiring multiple therapeutic interventions.